Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials
Press release – For immediate release – 5:45pm CET
Median Technologies launches iSee®– a comprehensive technology platform to enhance medical imaging analysis in clinical trials – New platform enables high quality, accurate and predictive data for critical imaging endpoints
Median Technologies inks a collaboration agreement with Memorial Sloan Kettering Cancer Center for a study dealing with prostate cancer
iBiopsy® is a groundbreaking investigational imaging platform developed by Median, enabling the combination between imaging biomarkers and Phenomics. The collaboration supports the expansion of Median’s iBiopsy® to prostate cancer management
Median Technologies to attend the 103rd Scientific Assembly and Annual Meeting of the RSNA, to be held from November 26 to December 1, 2017 in Chicago, IL, USA
Median will feature its investigational imaging biomarker phenotyping system iBiopsy® and its advanced imaging analysis technology MediScan® at Booth #3203 South Hall A.
Median Technologies awarded “Listed Company of Région Méditerranée” from Deloitte/In Extenso Technology Fast 50 2017
Median Technologies awarded “Listed Company of Région Méditerranée” from Deloitte/In Extenso Technology Fast 50 2017 – Median is the fastest growing listed company of Région Méditerranée within the last 4 years (2013-2016).
Median Technologies appoints Dr. Peter Bannister as Chief Technology Officer
As Chief Technology Officer, Dr. Bannister is responsible for leading the development and scientific research teams at Median and ensuring that Median’s products directly address the unmet healthcare needs identified by the company’s clinical end users. Peter Bannister brings more than 15 years of experience developing novel imaging products.